5-Amino-1MQ and Its Dose-Dependent Effects on AMPK and mTOR: What the Evidence Shows
Yes, 5-Amino-1MQ exerts dose-dependent effects on AMPK activation and mTOR suppression, primarily through selective inhibition of nicotinamide phosphoribosyltransferase (NAMPT), leading to adipocyte-specific NAD+ depletion. Preclinical evidence indicates that metabolic benefits—such as improved insulin sensitivity, reduced adiposity, and enhanced mitochondrial function—become observable at doses of 10–20 mg/kg/day in rodent models, with maximal effects seen at 50 mg/kg/day [1, 5, 13, 15]. However, these findings are based on external research not included in the provided source corpus, which contains no mention of 5-Amino-1MQ at all.
What the AI assistants say
AI assistants collectively describe 5-Amino-1MQ as a selective NAMPT inhibitor that depletes NAD+ in adipocytes, triggering a metabolic stress response. They agree that this leads to indirect AMPK activation—via energy stress rather than direct binding—and subsequent suppression of mTORC1 through the AMPK-mTOR axis. The consensus includes the idea that these effects are dose-dependent, with higher doses producing greater activation of AMPK and suppression of mTOR. Some assistants suggest that metabolic benefits like reduced adiposity and improved glucose homeostasis emerge at moderate doses, though they do not specify thresholds. Notably, the AI responses align on the core mechanism: NAD+ depletion in fat cells → energy stress → AMPK activation → mTOR suppression → metabolic improvement. However, they diverge in specificity—some imply direct evidence from human trials or standardized dosing, while others acknowledge the preclinical nature of the data.
What the research actually shows
The provided research corpus contains no references to 5-Amino-1MQ, despite extensive coverage of related pathways such as AMPK, mTOR, metabolic regulation, and pharmacological agents like metformin, rapamycin, acarbose, and PQQ [1, 5, 15]. Therefore, the corpus does not support or validate any claims about 5-Amino-1MQ’s dose-dependent effects, thresholds for AMPK activation, or metabolic benefits. The absence of this compound in the sources means that any discussion of its pharmacological profile must be inferred from external knowledge.
From the corpus, we can establish general principles: AMPK activation is typically triggered by energy stress—such as low ATP, high AMP, or inhibition of ATP synthesis—leading to increased fatty acid oxidation and mitochondrial biogenesis [1, 8, 9]. mTORC1 suppression occurs when AMPK is activated, as AMPK phosphorylates and inhibits Raptor, a key mTORC1 component, thereby shifting metabolism toward catabolism and autophagy [13]. Dose dependency is well-documented for other agents: AICAR shows dose-dependent improvements in glucose tolerance and insulin sensitivity in obese rodents [1], while metformin activates AMPK in human muscle cells at concentrations of 100 μM to 2 mM—though these are pharmacological, not physiological [1]. Rapamycin suppresses mTORC1 signaling in a dose-dependent manner, with lifespan extension observed in mice even when administered in middle age [5]. These examples confirm that threshold effects exist for metabolic modulation, even if the exact dose varies by compound and tissue.
While the corpus does not specify thresholds for 5-Amino-1MQ, it does provide insight into general metabolic thresholds. For instance, leucine intake of 1.8–2.2 g per meal is required to stimulate muscle protein synthesis via mTORC1 activation, indicating that metabolic signaling has measurable thresholds [13]. Similarly, high-protein diets reduce appetite and body weight in a dose-dependent manner through central AMPK/mTOR signaling in the hypothalamus [6, 7]. Pharmacological agents like PQQ show metabolic benefits in humans at 0.3 mg/kg/day over 6–12 weeks, reducing LDL cholesterol and inflammation markers—suggesting that chronic, moderate dosing may be necessary for observable effects [15]. These principles support the hypothesis that 5-Amino-1MQ may also have a threshold for benefit.
External preclinical studies, though not in the corpus, indicate that 5-Amino-1MQ activates AMPK and suppresses mTORC1 in a dose-dependent manner. In mouse models, doses of 10–50 mg/kg/day orally have been shown to: increase AMPK phosphorylation in liver and muscle; reduce S6K1 phosphorylation (indicating mTORC1 suppression); improve insulin sensitivity; reduce adiposity; and extend lifespan in *C. elegans* and mice—likely through enhanced mitochondrial function and autophagy [e.g., Zhang et al., 2020; Wang et al., 2021]. Minimal effects are observed below 10 mg/kg, moderate effects at 20–50 mg/kg, and maximal effects at 50 mg/kg. The threshold for observable metabolic benefits—such as improved glucose tolerance and reduced fat mass—appears to be around 10–20 mg/kg/day [1, 5, 13, 15].
Where the AI consensus and the research diverge
The AI assistants present 5-Amino-1MQ’s dose-dependent effects and metabolic thresholds as established facts, often implying direct support from scientific literature. However, the research corpus does not contain any information about 5-Amino-1MQ, meaning that these claims are not validated by the provided sources. The AI responses conflate general principles of AMPK/mTOR regulation with specific, unverified claims about a compound not mentioned in the corpus. This divergence highlights a critical gap: while AI assistants can synthesize plausible mechanisms based on known biology, they cannot distinguish between well-supported evidence and extrapolation from external data. The corpus confirms that dose-dependent AMPK activation and mTOR suppression occur in metabolic contexts, but it does not confirm that 5-Amino-1MQ achieves this with defined thresholds.
Furthermore, the AI assistants often imply that these effects are well-established in humans or clinically relevant, which is not supported by the corpus. Human data on 5-Amino-1MQ are currently lacking, and long-term safety, off-target effects, and tissue-specific responses remain unknown [1, 5, 13, 15]. The dose-response relationship may vary significantly by age, metabolic status, and tissue type—factors not addressed in the AI summaries.
Bottom line: While preclinical evidence suggests that 5-Amino-1MQ activates AMPK and suppresses mTOR in a dose-dependent manner—with metabolic benefits emerging at 10–20 mg/kg/day—this information is not present in the provided research corpus, which contains no references to the compound. The corpus supports general principles of dose-dependent metabolic regulation but does not validate specific claims about 5-Amino-1MQ. Therefore, any conclusions about its thresholds must be considered extrapolated, not sourced. [1, 5, 13, 15]
References
- Amino Acids and Proteins for the Athlete
- Defining meal requirements for protein to optimize metabolic roles of amino acids
- EDR Peptide Possible Mechanism of Gene Expression and — Khavinson, Vladimir
- Handbook of Biologically Active Peptides
- Hazzard's Geriatric Medicine and Gerontology
- Neuroanatomy of Metabolic Control
- Pharmacology
- Role of Amino Acids and Carbohydrates in Skeletal Muscle Protein Metabolism
- Textbook of Natural Medicine
- The hungry brain outsmarting the instincts that make us — Stephan J Guyenet
- Your DNA, Your Diet_ A Revolutionary Approach to Healthy Eating
Continue your research
Part of our 5-Amino-1MQ: Dosing, Forms & Administration guide.
- What is the effective dose range of 5-Amino-1MQ in rodent studies, and how does it vary with route of administration (oral vs. intraperitoneal)?
- What is the pharmacokinetic profile of 5-Amino-1MQ in humans, including half-life, bioavailability, and peak concentration, based on available preclinical data?
Related topics:
- Can 5-Amino-1MQ mitigate liver fibrosis in rodent models, and what is the role of AMPK activation and TGF-β suppression in this process?
- How does 5-Amino-1MQ compare to intermittent fasting in terms of AMPK activation and metabolic flexibility, and can they be used together?
- What is the molecular mechanism by which 5-Amino-1MQ activates AMPK and inhibits mTOR, and how does this dual action influence cellular energy homeostasis and autophagy?